

SUBJECT INDEX

A

- Acetyl-coenzyme A (CoA), 40, 180, 186, 189–91, 332–33
continuous regulation of, 40
Acetyl-coenzyme A carboxylase (ACC), 332–33
Acinotobacter calcoueticus 69/V, 43–44
Acrodermatitis, 3, 442
Actinomycin D, 336
Acylcarnitine, 179, 188–98
deficiency, 190–98
esters, 56–57
Acyl-coenzyme A, 179–80, 186, 189–91, 193
Acyl-coenzyme A:retinol acyltransferase (ARAT), 262, 270–71
Adenyl cyclase, 354–56
Adipose tissue
glucose homeostasis and, 209, 219–20
glycerol-3-phosphate acyltransferase expression in, 335
Adrenocorticotropic hormone (ACTH), 65
Aging
osteoporosis and, 233–53
vitamin D receptor polymorphisms and, 233, 240, 243–53
AIDS
dietary oxidative stress and pathogenesis of, 93, 108, 111
A-kinase anchoring proteins (AKAPs), 357
Angiotensin-converting enzyme, 9
Antioxidants
carotenoids, 20
Apo-cellular retinol-binding protein (apoCRBP), 267
Apolipoprotein AI regulatory protein-1 (ARP-1), 306, 312
Apolipoprotein E, 303, 306
Apoptosis, 150
Ascorbic acid
glycosides of, 278, 292
ATF-1, 368–69
Atherosclerosis
cholesterol ester transfer protein and, 297, 318–32

Atherosclerotic cardiovascular disease
potential of inulin for risk reduction of, 117

B

- Bacillus subtilis*, 42
Bactericidal/permeability increasing protein (BPI), 298–323
Benzylamine oxidase, 151
Bifidogenic bacteria
inulin-type fructans and, 124–26
Bile, 386
Bile salt-dependent retinyl ester hydrolase (BSDREH), 264–66, 268, 272
Bile salt-independent retinyl ester hydrolase (BSIREH), 266–79
Bioavailability
zinc, 1, 4–6
calcium-phytate interactions, 6
casein-gelatin-based diets, 4–6
soy protein diets, 5–6
Body composition of livestock, 63–84
genetic engineering, 63, 78–84
antisense or ribozyme strategies, 81
gene inhibition, 81
inducible gene expression, 80
somatic cell engineering, 83–84
target genes, 82
transgenic livestock, 79–80
growth promoters, 77–78
hormone patterns and, 74
nutritional manipulation, 76–77
postnatal development, 72–76
prenatal development, 65–72
gender and, 72
insulin levels and, 72
protein accretion rate and, 74
Bone-mineral density (BMD), 235–53
genetic association studies, 239–53
age and, 245
apolipoprotein E phenotype, 242

body composition and, 245–47
calcium intake and, 247, 249
collagen gene polymorphisms, 242
estrogen receptor gene polymorphisms, 241–42
race and, 245
vitamin D receptor gene polymorphisms, 243–53
vitamin D supplementation and, 249–50

γ-Butyrobetaine

carnitine metabolism in microorganisms and, 39, 41–42, 44–47

Buyrobetaine hydrolase, 181–83

C

- Calcium-channel function
zinc and, 1, 12–15
Calcium metabolism, 233–53
osteoporosis and, 233–53
intestinal calcium absorption, 250–51
vitamin D receptor polymorphisms and, 233, 240, 243–53
Calcium-phytate interactions
zinc and, 6
cAMP, 343–44, 353–72
regulation of fatty acid synthase generation and, 343–44
regulation of nutritional metabolism and energy and, 354
cAMP response element binding protein (CREB), 353–55, 360–72
binding protein (CBP), 262–65
cAMP response element modulator (CREM), 353, 367–68
cAMP signaling pathway, 354–72
adenylyl cyclases and, 354–56
phosphatases, 359
PKA and, 353–59
PKA inhibitors, 358–59
transcription factors, 359–72
AP-2, 269
ATF-1, 368–69

- CREB, 360–67
 CRM, 367–68
 $\text{NF-}\kappa\text{B}$, 369
 nuclear receptors, 370–71
- Cancer, 344, 413–32
 lipogenic enzyme control and, 344
 see also Prostate cancer
- Carbonic anhydrase, 3
- Carboxylesterases
 hydrolysis of retinyl esters and, 259–60, 264–69
- Carnitine
 acyl-, 179, 188–98
 biosynthesis, 53, 180–82
 deficiency, 179, 184–88, 190–98
 nutritional interventions, 197–98
- functions, 40–41
 genetic disorders, 179–98
 homeostasis, 53–57
 kidneys and, 53–57
- insufficiency, 186–87
- metabolism, 39–57
 bacterial degradation, 47
 exercise and, 52–53
 in mammals, 46–56
 in microorganisms, 41–44
- nutrition, 187–88
- transport, 182–88
 defects, 179, 184–88
 defects in, 184–88
- Carnitine palmitoyltransferase (CPT), 179, 189–98
- Carotenoids, 19–33
 α -, 20, 25–26
 bioavailability, 25
 β , 20–33
 bioavailability, 25–26
 matrix, 27
 sex and age and, 32
- Carotenoids, 19–33, 413, 428–29
 alcohol intake and, 29–30
 bioavailability and
 bioconversion, 20–33
 matrix and, 27–28
 methods for determining, 21–22
 SLAMENGHI, 22–33
- bioconversion to retinol, 19–33
 dietary fat and, 29
 dietary fiber and, 29
 prostate cancer risk and, 413, 428–29
- Casein-gelatin-based diets, 4–6
 zinc and, 4–6
- Cellular retinol-binding protein, 272
- Chicory, 117
- Cholesterolemia
 inulin-type fructans and, 131–32
- Cholesteryl ester transfer protein (CETP)
 atherosclerosis and, 297, 318–23
 gene expression, 301–9
 diet and, 302–9
 endogenous
 hypercholesterolemia and, 302–9
- insulin resistance and, 309–10
 mechanism of neutral lipid transfer, 300–1
- structure, 298–300
- transgenic mice studies, 303–8, 310–12, 318–19
- Collagen
 lysyl topa quinone and, 154
- Colon, 117
- Colostrum, 73
- Constipation
 potential of inulin for risk reduction, 117
- Copper, 15–16, 153, 441, 451–56
 deficiency, 153
 ion transport, 441, 451–56
- Copper-containing amine oxidases, 145–67
 cysteinyl-tyrosine (CT), 145, 148–50, 153
- lysyl topa quinone (LTQ), 145–50, 154–55, 161–67
- pyrroloquinoline quinone (PQQ), 145–50, 155–67
- topa quinone, 145–54, 161–67
- diamine oxidase (DAO), 150–54, 162–64, 166
- monamine oxidases (MAO), 150–54, 164, 166
- plasma amine oxidase (PAO), 150–54, 164, 166
- semicarbazide-sensitive amine oxidase (SSAO), 150–54, 164, 166–67
- see also Redox cofactors
- Corticotropin-releasing factor (CRF), 65
- Corynebacterium glutamicum*, 42
- Coxsackievirus pathogenesis
 dietary oxidative stress and, 93, 95–100, 108, 110–12
- iron toxicosis and, 99
- selenium deficiency and, 93, 95–97, 100
- vitamin E deficiency and, 93, 98
- CREB, see cAMP response element binding protein
- CREB-binding protein (CBP), 362–65
- Crotonobetaine
 carnitine metabolism in microorganisms and, 39, 44–47
- Cyclic adenosine monophosphate, see cAMP
- Cyclic AMP, see cAMP
- Cyclohexamide, 336
- Cysteinyl-tyrosine (CT), 145, 148–50, 153
- D**
- Diabetes mellitus, non-insulin dependent (NIDDM, type 2)
 inulin and potential for risk reduction, 117
- lipogenic enzyme control and, 344
- transgenic mice studies, 209–27
 adipose tissue, 209, 219–20
 liver, 209, 220–25
 pancreatic β -cells, 207, 209–13
 skeletal muscle, 209, 213–19
- Diamine oxidase (DAO), 150–54, 162–64, 166
- Diarrhea
 potential of inulin for risk reduction, 117
- Dihydrotestosterone, 419
- DNA-binding proteins
 zinc and, 12
- DNA synthesis
 zinc and, 7–8, 12
- E**
- Ecdysone, 80
- Enteropathica, 442
- Escherichia coli*, 44, 46–47
- N-Ethylmaleimide (NEM), 335
- F**
- Fanconi syndrome, 187
- Fatty acid biosynthesis, 331–45
 fatty acid synthase and, 334
- mitochondrial
 glycerol-3-phosphate acetyltransferase (GPAT) and, 331, 334

Fatty acid oxidation
mitochondrial carnitine system
and, 189–97
mitochondrial
acylcarnitine-carnitine
translocase and, 192–93

Fatty acids
prostate cancer risk and, 413,
421–24

Fatty acid synthase (FAS),
331–45
transcriptional regulation of
genes, 331, 334–45
glucagon and, 336–38,
343–44
insulin and, 336–43

Feed-conversion ratio, 64
somatotropin/insulin-like
growth factor and, 64

Fermentation
dietary fructans and, 117–38
in vivo, 124–26
large bowel, 123, 126–27
products of digestion, 126
tequila, 119

Fibroblast growth factor (FGFs),
66–69

Fructans, 117–38
define, 118
as dietary carbohydrate,
119–20
chemistry, 118
fermentation, 117–38
health claims and scientific
evidence, 133–38
large bowel, 123, 126–27
glycemia modulation, 129–30

inulin, 117–38
plant sources, 118
triglyceridemia and, 130–32
types used in food industry,
119–20
uremia and, 132
see also Inulin

G

Gene therapy, 63, 78–84
Genetic engineering
livestock body composition and,
63, 78–84
antisense or ribozyme
strategies, 81
gene inhibition, 81
inducible gene expression, 80
somatic cell engineering,
83–84
target genes, 82
transgenic livestock,
79–80

Germline transgenesis, 63,
78–84
Glucagon, 331, 336–38,
343–44
regulation of fatty acid
synthase gene and,
343–44

Glucocorticoids, 65, 331

Glucogenesis
cAMP and, 354
phosphoenolpyruvate
carboxykinase (PEPCK)
and, 354

Glucose, 162–63, 207–27,
331–34, 336–44
fatty acid synthase transcription
and, 336–44
glycerol-3-phosphate
acyltransferase (GPAT)
transcription and, 336–43

hexosamine biosynthesis and,
217–18
homeostasis, 207–27
insulin-mediated signal
transduction and, 218–19
ion channel conductance, 213
metabolism
transgenic mice studies,
207–27
monoxide glucose disposal,
217
oxidase, 162–63
phosphorylation, 211–13,
216–17
transport, 211, 214–16

Glucosides, 277–93
ascorbic acid, 278, 292
niacin, 277, 289, 293
pantothenate, 277, 291–92
pyridoxine, 277
retinol, 277, 291
riboflavin, 277, 288–89
vitamin B₆, 278–88, 293
vitamin D, 277–78, 290–91

Glycemia
fructans and modulation of,
129–30

Glycerol-3-phosphate
acyltransferase (GPAT),
331–45
isoforms of, 335
transcriptional regulation of
genes, 331, 334–45
glucagon and, 336–38
insulin and, 336
nutritional and hormonal,
335–38

Glycogen
role of cAMP and PKA in
breakdown of, 354

Gold thioglucose, 99–100

Growth differentiation factor-8
(GDF-8), 69
Growth hormone releasing factor
(GRF), 65, 71, 79
transgenic augmentation of, 79

H

Haumophilus influenzae, 42

Hemochromatosis, 442

Hepatitis pathogenesis
dietary oxidative stress and,
93, 98

iron toxicosis and, 98–99
High-density lipoprotein (HDL),
297–301, 311–12, 315–17,
320–21, 323

Hip axis length (HAL), 235

Histaminase, see Diamine oxidase
Histone acetyltransferase (HAT),
363

Hydrolases, 259, 264–73
bile salt-dependent retinyl ester
hydrolase, 264–66, 268,
270, 272
bile salt-independent retinyl
ester hydrolase, 266–70,
272

Hyperlipidemia
lipogenic enzyme control and,
344

I

Inducible cAMP early repressor
(ICER), 368

Influenza pathogenesis
dietary oxidative stress and, 93,
99–100, 108–12
gold thioglucose and, 99–100
host immune system and,
100–3

Inulin, 117–38
calcium absorption, 128
chicory, 117, 119–21
as dietary carbohydrate, 120–21
classification, 121
sources, 120–21
fermentation
in large bowel, 123
in vitro, 123
in vivo, 124–26
health claims and scientific
evidence, 133–38
potential in risk reduction of
disease, 117, 134–38
triglyceridemia and, 130–32
types used in food industry,
119–20
uremia and, 132

- I**
- Insulin, 331, 336–43
gene regulation and
fatty acid synthase and
glycerol-3-phosphate
acyltransferase, 336–43
type-2 diabetes and, 209–27
adipose tissue, 209, 219–20
glucose homeostasis and,
208–27
liver, 207, 209, 220–25
pancreatic β -cells, 207,
209–13, 226–27
skeletal muscle, 207, 209,
213–19
resistance
cholesterol ester transfer
protein and, 309–10
- Insulin-like growth factors, 65,
67–77
binding proteins (IGFBPs), 69,
75–77
body composition and
nutritional manipulation, 76
patterns of development, 76
- I, 65–68
II, 68
transgenic augmentation of, 79
- Iron**
ion transport, 441, 443–51
overload, 98–99
chronic hepatitis and, 98–99
vitamin E as antidote, 98
- K**
- Keshan disease, 95, 108–9
Kidneys
carnitine homeostasis and,
53–57
- Kinase inducible domain (KID),
361
- Knockout mice
macrophage inflammatory
protein 1 α , 104
glutathione peroxidase 1,
105–7
- L**
- Lecithin, 28
Lecithin:retinol acyltransferase
(LRAT), 262, 271–72
- Lecithyl cholesterol
acyltransferase (LCAT), 301,
319
- Levan, 118
- Lipases
hydrolysis of retinyl esters and,
259–60, 264, 269–71
- Lipogenesis, 331–45
Lipopolysaccharide binding protein
(LBP), 298–99, 301
- Liver**
chromatin structure of, 341
enzymes catalyzing hydrolysis
of retinyl esters, 259–73
glucose homeostasis and,
220–25
alterations in insulin action,
223, 225
hepatin glucose uptake and
output, 220–23
glycerol-3-phosphate
acyltransferase expression
in, 335
- Livestock, see Body composition
of livestock
- Low-density lipoproteins (LDL),
303, 311, 316–17, 322
- Lycopene, 26, 28, 428–29
Olestra and reduced plasma
concentrations of, 429
prostate cancer risk reduction
and, 428–29
- Lysine**
carnitine biosynthesis and, 53
- Lysyl oxidate (LO), 155, 159, 166
- Lysyl topa quinone (LTQ),
145–50, 154–55, 161–67
medical and other uses, 161–67
- M**
- Manganese ion transport, 441,
457–60
- Melanogenesis, 161
- Menkes disease (syndrome),
153–55, 442
- Metal ion transport, 441–63
copper, 441, 451–56
iron, 441, 443–51
manganese, 441, 457–60
zinc, 441, 460–63
- Metalloenzymes
zinc and, 11–12
- Metallothionein gene
zinc and, 80
- Methionine
carnitine biosynthesis and, 53
- Methylamine dehydrogenase
(MADH), 149
- Mitochondrial carnitine system,
189–97
fatty acid oxidation and,
189–97
- mitochondrial
acylcarnitine-carnitine
translocase, 192–93
deficiency, 193
- Monoamine oxidases (MAO),
150–54, 164, 166
- Mouse mammary tumor virus
(MMTV) promoters, 370
- Mucins, 386
- Muscle development
maternal influences, 70–72
proliferation and differentiation,
66–70
somatotropin/insulin-like
growth factor axis and,
63–64
stages, 65
- Myocyte-specific
enhancer-binding factor 2
(MEF2), 66
- Myogenesis, 65–72
see also Muscle development
- Myogenesis determination factor
(MyoD), 66–70
- Myoglobinuria
exercise-induced, 195
- Myostatin, 83
- N**
- NADPH, 332
- Nerve function
zinc and, 1, 10–11
- Niacin
glycosides of, 277, 289, 293
- Nitrogen cycling, 385–406
amino acids, 395–406
bile, 386
cell debris, 386
digesta, 387–95
gastrointestinal tissue and,
402–6
glutathione and, 380
mucins, 386
protein synthesis and,
386–406
secretions into gut, 386–87
urea, 386, 393–95
- Nuclear factors, 353
- O**
- Obesity
diabetes type-2 and, 209
lipogenic enzyme control and,
344
- Olestra
reduction of plasma
concentrations of lycopene
and, 429
- Oligofructose, 117
- Omega-3 fatty acids, 97–98
- Osteoporosis, 233–53

- age and, 245
 apolipoprotein E phenotype, 242
 body composition and, 245–47
 collagen gene polymorphisms, 242
 diet and, 236
 genetic association studies, 239–44
 bone mineral density and, 239–44
 hip axis length and, 235
 low bone mineral density and, 235
 peak bone mass and, 235
 race and, 236–37
 vitamin D
 receptor gene polymorphisms, 243–53
 supplementation, 249–50
- Oxidation-reduction (redox)
 cofactors, 145–67
 see also Copper-containing amine oxidases
- Oxidative stress
 defined, 94
 dietary, 93–112
 gold thioglucose and, 99–100
 host immune system and, 100–3
 iron overload, 98–99
 selenium deficiency, 93–97, 199
 viral infection and, 94–100
 vitamin E deficiency, 93, 97–98
- P**
- Pancreatic β -cells, 207–13, 226–27
 diabetes type-2 and, 207, 209–13, 226–27
 glucose homeostasis and, 208–13
 glucose phosphorylation, 211
 glucose transport, 211
 ion channel conductance, 213
 Patothenate
 glycosides of, 277, 291–92
 Peak bone mass, 235, 245
 PEPCK, see Phosphoenolpyruvate carboxykinase
 Peroxisome proliferator-activated receptor (PPAR), 337
 Phosphatases, 359
 Phosphatidylinositol 3-kinase, 68, 343
 Phosphodiesterases, 350
 Phosphoenolpyruvate
 carboxykinase (PEPCK), 334, 337, 342–43, 354
 cAMP stimulation of gene for, 354
 gene repression by insulin, 342–43
 Phospholipid transfer protein (PLTP), 297–323
 gene expression
 diet and, 302–9
 endogenous
 hypercholesterolemia and, 302–9
 reverse cholesterol transport and, 315–17
 Picornavirus family, 94
 Plasma amino oxidase (PAO), 150–54, 164, 166
 Plasma lipid transfer proteins, 297–323
 atherosclerosis and, 318–23
 cholesterol ester transfer protein (CETP), 297–323
 phospholipid transfer protein (PLTP), 286–323
 reverse cholesterol transport and, 315–17, 321
 Plasma membrane function
 zinc and, 1, 12–15
 Polyunsaturated fatty acids (PUFA), 337–38
 Prebiotics
 inulin-type fructans, 124–26, 135
 Probiotics
 inulin-type fructans, 123
 Probucol, 308
 Prostate cancer
 age and, 416
 demographics, 418
 diet and nutrition and, 413–32
 endocrine factors, 419
 family history, 417
 histopathology, 415–16
 incidence, 417–18
 nutritional risk factors, 421–32
 alcohol, 424
 fatty acids, 421–24
 lycopen, 428–29
 protein, 421
 selenium, 429–30
 vitamin A, 426–28
 vitamin D, 430–31
 sexual and reproductive factors, 419
 Protein kinase A (PKA), 353–73
 inhibitors, 358–59
 phosphorylation and activation of transcription factors by, 353–73
 regulation of nutrient metabolism and, 354
 subunits, 356–58
Pseudomonas, 42
 Pyridosine
 glycosides of, 277, 279–88, 293
 enzymatic hydrolysis, 284–86
 intestinal absorption, 283–84
 vitamin B₆, 278–88, 293
 Pyrroloquinoline quinone (PQQ), 145–50, 155–67
 as essential nutrient, 157–61
 medical and other uses, 161–67
 Pyruvate, 332
 L-Pyruvate kinase, 334
- Q**
- Quinoproteins, 145–67
 as essential nutrients, 157–61
 medical and other uses, 161–67
- R**
- Reactive oxygen species
 influenza pathogenesis and, 101
 Redox cofactors, 145–67
 see also Copper-containing amine oxidases
- 11-cis Retinaldehyde, 260
 Retinoids, 259, 262
 Retinol, 19–33, 259–73
 bioconversion from carotenoids, 19–33
 alcohol intake and, 29–30
 dietary fat and, 29
 dietary fiber and, 29
 SLAMENGLI, 22–23
 zinc and, 31
 glycosides of, 277, 291
 metabolism, 259–73
 Retinyl ester hydrolases (REH)
 bile salt-dependent, 264–66, 268, 272
 bile salt-independent, 266–70, 272
 Retinyl esters, 259–73, 300
 digestion of, 261
 cholesterol ester transfer protein and, 300

vitamin A metabolism and, 260–62
 Reverse cholesterol transport cholesterol ester transfer protein and, 297, 315–17, 321
Rhodopsin, 260
Riboflavin
 glycosides of, 277, 288–89
RNA enterovirus, 94
 RU486, 80

S

Saccharomyces cerevisiae
 metal ion transport in, 441–63
Salmonella typhimurium, 44
 Scavenger receptor BI, 297, 304, 308
Selenium
 prostate cancer risk and, 429–30
 Selenium deficiency
 oxidative stress and, 93–97, 100, 108–10
 coxsackievirus B3 infection and, 93, 95–97, 100
 Keshan disease and, 95, 108–9
 Semicarbazide-sensitive amine oxidase (SSAO), 150
 Sex hormone binding globulin (SHBG), 419–20
 Signal transduction
 insulin-mediated, 218–19
 zinc and, 1, 12–15
 Signal transduction activating transcriptions (STATs), 363
 Skeletal muscle
 glucose homeostasis and, 207, 209, 213–19
 glucose phosphorylation, 216–17
 glucose transport, 214–16
 hexosamine biosynthetic pathway, 217–18
 insulin-mediated signal transduction, 218–19
 monooxidative glucose disposal, 217
 Sodium dodecyl-sulfate-polyacrylamide gel electrophoresis, 268
Somatotropin (ST), 63–64, 71–72, 76–79
 IGF-I and, 77–79
 transgenic augmentation of, 79
 livestock body composition and nutritional manipulation of, 76–78

Somatotropin/insulin-like growth factor axis, 64, 74–79
 body composition and nutritional manipulation of, 74–78
 patterns of development, 74–76
Somatostatin, 65, 72
 Soy protein diets
 zinc bioavailability in, 5–6
 Spermatogenesis, 353
 Sterol response element-binding proteins, 341

T

Thyroid hormone, 331
 Thyroid-stimulating hormone, 358
Topa quinone (TPQ), 145–50, 161–67
 uses, 161–67
 Trace element research, 1–16
 zinc and, 1
 Transforming growth factor- β , 66, 67, 69
 Transgenic livestock, 79–84
 Transgenic mice, 81–82, 303–8, 310–12, 318–19, 209–27
 bovine α -lactalbumin expression and, 81
 cholesterol ester transfer protein gene expression and, 303–8, 310–12, 318–19
 glucose metabolism studies, 209–27
 adipose tissue, 209, 219–20
 liver, 207, 209, 220–25
 pancreatic β -cells, 207, 209–13, 226–27
 skeletal muscle, 207, 209, 213–19
Translocase, 179
 Transurethral resection of the prostate (TURP), 418
 Triacylglycerol biosynthesis, 331–45
 mitochondrial glycerol-3-phosphate acyltransferase (GPAT) and, 331, 334–45
 Triglyceridemia
 inulin-type fructans and, 130
 Trimethylamine
 carnitine metabolism in microorganisms and, 39–44
 6-N-Trimethyllysine, 181–82
Tryptophan tryptophylquinone (TTQ), 145–59, 161–67

medical and other uses, 161–67
Tumor necrosis factor (TNF), 65

U

Urea, 386, 393–95
 Uremia, 132

V

Vascular cell adhesion molecule-1 (VCAM-1), 369
 Very low-density lipoprotein (VLDL), 311–12, 318
 Viral infection pathogenesis dietary oxidative stress and, 93–112
 gold thioglucose and, 99–100
 host immune system and, 100–3
 iron toxicosis and, 98–99
 knockout mice, 103–7
 selenium deficiency and, 93–97, 100
 vitamin E deficiency and, 97–98
 Viral mutation, 93
 Vitamin A
 carotenoids and, 19–33
 hydrolysis of retinyl esters and, 260–73
 metabolism and transport, 260–62
 prostate cancer risk and, 413, 426–28
 Vitamin B₆
 glycosides of, 278–88, 293
 Vitamin D
 glycosides of, 277–78, 290–91
 osteoporosis and, 233, 236
 prostate cancer risk and, 413, 430–31
 Vitamin D receptor polymorphisms
 osteoporosis and bone-mineral density, 233, 240, 243–53
 age and, 245
 body composition and, 245–47
 calcium intake and, 247, 249
 race and, 245
 vitamin D supplementation and, 249–50
 as predictor of disease, 252
 Vitamin E, 93, 97–98, 110, 156
 deficiency, 93, 97–98, 110
 iron overload and, 98
 oxidative stress and, 93, 98

Vitamin K, 236

W

Wilson disease, 442

Z

Zinc

angiotensin-converting enzyme
and, 9

bioavailability in food, 4–6
calcium-channel functions,
12–15
calcium-phytate interactions,
6
 β -carotene utilization and,
31
dietary fatty acids and, 8
DNA synthesis and, 7–8, 12
erythrocyte stability and,
10, 12
IGF-I and, 8

ion transport, 441, 460–63
locomotion and, 10–11
metalloenzymes and,
11–12
peripheral nerves and,
10–11
plasma membrane function and,
1, 12–15
retinol-binding protein
synthesis and, 31
signal transduction and, 1, 8–9,
12–15



